Ichor Medical Systems, whose advanced TriGrid(TM) Delivery System is being tested worldwide for its ability to enhance delivery of DNA drugs and vaccines, announced today that preliminary safety and tolerability data for a Phase I preventive HIV vaccine clinical trial being conducted at the Rockefeller University Hospital in New York City will be presented at the AIDS Vaccine Conference in Cape Town South Africa this week.

Ichor Medical Systems, whose advanced TriGrid electroporation system is being tested worldwide for its ability to enhance delivery of DNA drugs and vaccines, announced today that recruitment of patients has commenced for the final and highest dose level for their Phase I melanoma vaccine clinical trial in the study being conducted by Memorial Sloan-Kettering Cancer Center.

Ichor Medical Systems, whose advanced electroporation system is being tested worldwide for its ability to increase the effectiveness of DNA drugs and vaccines, has entered into an agreement with two distinguished research organizations to test a promising HIV vaccine, ADVAX, in human volunteers.

Ichor Medical Systems, whose advanced electroporation system is being used worldwide to increase the effectiveness of DNA drug and vaccine delivery, has been awarded a two-year contract valued at over $2.3 million by the Defense Threat Reduction Agency (DTRA).

Ichor Medical Systems has received FDA approval to conduct a phase I clinical trial of a melanoma vaccine to be administered to patients utilizing a novel delivery technology.